Search - tctmd.com

Displaying 1 - 20 of 31

Sort: Relevancy | Date

Presentation TCT 2024

TTVR – is the Future! Lessons from Clinical Trials and Case Experiences

Presenter: Azeem Latib

October 29, 2024

Presentation TCT 2024

Overview of IASD Trials: Where Do We Stand?

Presenter: JoAnn Lindenfeld

October 28, 2024

Presentation TCT 2024

Interatrial Shunts (IASD): From Theory to Clinical Trials

Presenter: Javed Butler

October 28, 2024

Presentation NY Valves 2024

Expanding Indications for LAAO to Front Line Therapy for Stroke Reduction in AF: Clinical Trial Updates

Presenter: Shephal K. Doshi

June 06, 2024

Presentation NY Valves 2024

The Future of Transcatheter Tricuspid Intervention: What’s Missing in Technology and Clinical Trials?

Presenter: Azeem Latib

June 06, 2024

Presentation TCT 2023

The Future of Transcatheter Therapies for AR: The Impact of the ALIGN-AR Trial

Presenter: Martin Leon

October 24, 2023

Presentation TCT 2022

Ongoing Clinical Trials and the Future of LAAC

Presenter: Matthew Price

September 18, 2022

Presentation TCT 2022

Expanding the Boundaries of MR Treatments with Early Results from the SUMMIT Trial

Presenter: Gorav Ailawadi

September 17, 2022

Presentation TVT 2022

The Future of Balloon-Expandable TAVR: SAPIEN X4 and the ALLIANCE Trial

Presenter: Tamim M. Nazif

June 08, 2022

Presentation TVT 2022

Heterotopic Tricuspid Valve Replacement: Considerations for Future Clinical Trials

Presenter: Ori Ben-Yehuda

June 08, 2022

Presentation TCT 2019

Focus FMR: Trial Data, Patient Selection, and Synergistic Therapies

Presenter: Michael Mack

September 28, 2019

Presentation TCT 2019

Pivotal Transcatheter FMR Device Trials: Future Perspectives One Year After COAPT and MITRA-FR

Presenter: Gregg Stone

September 27, 2019

Presentation TCT 2019

Clinical Trial Design Considerations for Next-to-Market and Next-Generation LAAO Devices

Presenter: Brian Whisenant

September 26, 2019

Presentation TCT 2019

LAA Closure vs. NOACs: Pros and Cons, PRAGUE 17, and Additional Trials

Presenter: Vivek Reddy

September 26, 2019

Presentation The Structural Heart Disease Summit 2018

Status Update of the EARLY TAVR Trial Asymptomatic Severe AS Patients

Presenter: Howard C. Herrmann, Allan Schwartz, Philippe Genereux

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Status Update of the TAVR UNLOAD Trial Moderate AS Patients With Reduced Ejection Fraction

Presenter: Howard C. Herrmann, Allan Schwartz, Nicolas M. Van Mieghem

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

NOTION 1 - Five-Year FU and Notion 2 - Young & Low-Risk

Presenter: Lars Sondergaard

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

UK All-Comers

Presenter: Neil E. Moat

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Evolut R Low-Risk

Presenter: Jeffrey J. Popma

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Partner 3 Low-Risk

Presenter: Martin B. Leon

June 21, 2018

Advertisement

TTVR – is the Future! Lessons from Clinical Trials and Case Experiences

Overview of IASD Trials: Where Do We Stand?

Interatrial Shunts (IASD): From Theory to Clinical Trials

Expanding Indications for LAAO to Front Line Therapy for Stroke Reduction in AF: Clinical Trial Updates

The Future of Transcatheter Tricuspid Intervention: What’s Missing in Technology and Clinical Trials?

The Future of Transcatheter Therapies for AR: The Impact of the ALIGN-AR Trial

Ongoing Clinical Trials and the Future of LAAC

Expanding the Boundaries of MR Treatments with Early Results from the SUMMIT Trial

The Future of Balloon-Expandable TAVR: SAPIEN X4 and the ALLIANCE Trial

Heterotopic Tricuspid Valve Replacement: Considerations for Future Clinical Trials

Focus FMR: Trial Data, Patient Selection, and Synergistic Therapies

Pivotal Transcatheter FMR Device Trials: Future Perspectives One Year After COAPT and MITRA-FR

Clinical Trial Design Considerations for Next-to-Market and Next-Generation LAAO Devices

LAA Closure vs. NOACs: Pros and Cons, PRAGUE 17, and Additional Trials

Status Update of the EARLY TAVR Trial Asymptomatic Severe AS Patients

Status Update of the TAVR UNLOAD Trial Moderate AS Patients With Reduced Ejection Fraction

NOTION 1 - Five-Year FU and Notion 2 - Young & Low-Risk

UK All-Comers

Evolut R Low-Risk

Partner 3 Low-Risk

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content